Definium Therapeutics (NASDAQ:DFTX - Get Free Report) had its target price raised by research analysts at JPMorgan Chase & Co. from $84.00 to $85.00 in a report released on Tuesday, Benzinga reports. The firm presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price objective would indicate a potential upside of 188.04% from the stock's current price.
Several other brokerages have also recently weighed in on DFTX. Oppenheimer reaffirmed an "outperform" rating and issued a $75.00 price target on shares of Definium Therapeutics in a research note on Monday, September 14th. Wall Street Zen raised Definium Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. JonesTrading raised their price objective on Definium Therapeutics from $74.00 to $90.00 and gave the company a "buy" rating in a research report on Thursday, August 13th. Piper Sandler restated an "overweight" rating and set a $75.00 target price (up from $73.00) on shares of Definium Therapeutics in a report on Friday, August 7th. Finally, Robert W. Baird upped their target price on shares of Definium Therapeutics from $75.00 to $79.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $66.29.
Get Our Latest Analysis on Definium Therapeutics
Definium Therapeutics Stock Down 2.2%
Definium Therapeutics stock traded down $0.65 during trading hours on Tuesday, hitting $29.51. 1,054,033 shares of the stock traded hands, compared to its average volume of 2,195,387. The firm's 50-day moving average price is $35.91 and its two-hundred day moving average price is $30.45. The company has a current ratio of 15.53, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. The company has a market cap of $3.97 billion, a PE ratio of -9.49 and a beta of 2.23. Definium Therapeutics has a one year low of $10.46 and a one year high of $49.70.
Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.09. On average, research analysts forecast that Definium Therapeutics will post -2.94 EPS for the current year.
Insider Buying and Selling
In other news, insider Mark Sullivan sold 14,051 shares of the stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $513,845.07. Following the sale, the insider directly owned 494,228 shares of the company's stock, valued at approximately $18,073,917.96. This represents a 2.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Matthew Wiley sold 3,097 shares of the firm's stock in a transaction on Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $113,257.29. Following the transaction, the insider owned 359,036 shares of the company's stock, valued at $13,129,946.52. The trade was a 0.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 71,098 shares of company stock valued at $2,626,115. 2.40% of the stock is owned by insiders.
Institutional Trading of Definium Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in Definium Therapeutics by 28.3% in the third quarter. GAMMA Investing LLC now owns 1,555 shares of the company's stock worth $59,000 after buying an additional 343 shares during the last quarter. Commonwealth Equity Services LLC lifted its stake in shares of Definium Therapeutics by 4.0% in the third quarter. Commonwealth Equity Services LLC now owns 9,832 shares of the company's stock worth $374,000 after buying an additional 382 shares in the last quarter. Heritage Wealth Management Inc. CA grew its holdings in shares of Definium Therapeutics by 3.3% during the third quarter. Heritage Wealth Management Inc. CA now owns 12,400 shares of the company's stock valued at $472,000 after buying an additional 400 shares during the last quarter. TD Waterhouse Canada Inc. grew its holdings in shares of Definium Therapeutics by 1.2% during the third quarter. TD Waterhouse Canada Inc. now owns 37,147 shares of the company's stock valued at $1,396,000 after buying an additional 453 shares during the last quarter. Finally, Fiduciary Financial Advisors increased its position in shares of Definium Therapeutics by 6.1% during the third quarter. Fiduciary Financial Advisors now owns 7,943 shares of the company's stock valued at $302,000 after acquiring an additional 460 shares in the last quarter. 27.91% of the stock is currently owned by institutional investors.
Definium Therapeutics Company Profile
(
Get Free Report)
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Definium Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Definium Therapeutics wasn't on the list.
While Definium Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.